Forest Laboratories agrees to acquire Aptalis for $2.9 billion
MLex Summary: NYSE-listed drugmaker Forest Laboratories has agreed to acquire privately held leading specialty pharmaceutical company Aptalis for $2.9 billion in cash. The deal is expected to close in the first half of 2014.Statement follows in...To view the full article, register now.
Already a subscriber? Click here to view full article